Skip to main content

Table 1 Baseline characteristics

From: Adverse effects of remdesivir for the treatment of acute COVID-19 in the pediatric population: a retrospective observational study

Overall cohort (n = 65)

Number, %

Male sex

41 (63)

Median age (years)

8.7 (IQR 3–15 years; range 3 months–18 years)

Patient age

 

 < 6 months old

3 (5)

 6 months–4 years old

20 (31)

 5 years old–11 years old

16 (24)

 ≥ 12 years old

26 (40)

Pre-existing comorbidities

 

 Pulmonary

20 (31)

 Cardiac

4 (6)

 Hematologic/oncologic

20 (31)

 Neurologic

13 (20)

 Chromosomal abnormality

7 (11)

 Obesity

13 (20)

Patients with ≥ 3 comorbidities

23 (35)

Mild-moderate COVID-19, high-risk for severe disease (n = 22)

 

Male sex

14 (64)

Median age (years)

8.5 (IQR years 4.5–14.5 years; range 1–17 years)

Patient age

 

 < 6 months old

0 (0)

 6 months–4 years old

6 (27)

 5 years old–11 years old

9 (41)

 ≥ 12 years old

7 (32)

Risk factor for severe disease

 

 Malignancy

13 (59)

 Hematologic disorder, non-malignant)

5 (23)

 Neurologic

2 (9)

 Other immunocompromised state

2 (9)